DKK1 is secreted by MM cells and therefore elevated local levels of DKK1 has been confirmed in the pathogenesis of MM‐induced bone loss.(19, 20, 21) Therapeutic inhibition of DKK1 increased bone formation and prevented bone loss in experimental models of myeloma.(22, 23) Therefore, we hypothesized that this novel combination receptor/antagonist targeted approach would be superior in preventing MM‐induced bone disease. Here, DKK1 is linked to Miyoshi myopathy.